Learn
GLP-1 Learning Hub
Curated articles, videos, and research — AI-summarized so you get the key insights fast.
Article
Gila·6/17/2026
Moving Less on GLP-1: The Activity Drop Nobody Warns You About
A 2026 study using Fitbit data found people on GLP-1s moved less, not more — daily steps fell from 5,047 to 4,487. Here's why your body quietly slows down when you eat less, and the gentle way to protect muscle with movement and enough protein.
Read more →
Article
Gila·6/17/2026
GLP-1 Persistence Statistics 2026: The Start-and-Stop Numbers, Honestly
GLP-1 persistence statistics for 2026, read honestly: how many people stop (about 4 in 10 in year one), how many restart (most of them), why they pause, and the behavior layer that separates regain from kept loss. Every figure linked to a primary source.
Read more →
Article
Gila·6/17/2026
Stopping and Restarting GLP-1 Is Normal — Here's What Holds the Loss
💡 **Your Journey, Your Habits!** New data from ENDO 2026 reveals that stopping and restarting GLP-1 medication is a common chapter for many, not a failure! This isn't about perfection, but about realizing that what truly anchors your weight loss through any pause are the powerful habits you build. So, let's use this window to focus on creating a sustainable foundation that outlasts any prescription!
Read more →
Article
Gila·6/13/2026
Food Noise and the Win Beyond the Scale
🤯 **Mind Shift!** Our latest insights reveal that for many, the true superpower of GLP-1s isn't just weight loss, but the incredible peace that comes from the "food noise" finally going quiet. This mental freedom, backed by emerging science on brain reward pathways, is a profound non-scale victory that transforms daily life and deserves every bit of celebration!
Read more →
Article
Gila·6/13/2026
The Things a Tracker Can't Measure
On a GLP-1, your hunger and fullness signals are changing, which makes relearning to listen to your own body a quiet superpower. This piece reframes the scale and trackers as companions, not verdicts, and names the non-scale victories data can't see.
Read more →
Article
Gila·6/13/2026
Do GLP-1s Change Your Personality? What the Mood Science Says
❤️ **Mind-Body Magic!** Ever wonder if your GLP-1 is doing more than just quieting food noise? New insights reveal these meds also tap into your brain's reward circuits, meaning shifts in mood, motivation, and even 'personality' are real and worth exploring. Listen to your body and always chat with your care team about any changes!
Read more →
Article
Gila·6/10/2026
ADA 2026 Scientific Sessions: The GLP-1 Data That Matters
The 2026 ADA Scientific Sessions delivered the GLP-1 era's biggest weight-loss number yet — retatrutide at about 28% — plus the first oral GLP-1 to beat semaglutide and three new contenders. Here is what actually landed, what is still investigational, and what it means for your journey.
Read more →
Article
Gila·5/28/2026
Generic Semaglutide Spreads: The Hims & Hers Canada Signal
Hims & Hers launched generic semaglutide in Canada for about $107 USD a month after Novo Nordisk lost its Canadian patent. It's a preview of post-patent GLP-1 pricing — and a reminder of why a true generic is still years away in the US. What the launch signals for 2026.
Read more →
Article
Gila·5/28/2026
Retatrutide Phase 3 Results: 30% Weight Loss and the Asterisk
Eli Lilly's triple agonist retatrutide posted its first Phase 3 results: roughly 25-28% mean weight loss at 80 weeks, with 45% of high-dose participants losing over 30% of body weight. The asterisk: an 11.3% side-effect discontinuation rate. What TRIUMPH-1 means if you're on a GLP-1 now.
Read more →
Original
Gila·5/28/2026
GLP-1 Weight Loss Statistics: The 2026 Numbers That Matter
🔥 **The Real GLP-1 Story!** While the latest stats show incredible weight loss potential with new meds like Retatrutide reaching up to 28% mean loss, the quiet but crucial number is *persistence*. Remember, the medication opens a powerful window, but it's the habits and support *you* build around it that truly determine your long-term success, helping you beat the high discontinuation rates and make those amazing trial results a reality for *your* journey!
Read more →
Article
Gila·5/25/2026
The GLP-1 Stigma Paradox — Rice Study Finds Medication Users Judged More Harshly Than Non-Losers
🗣️ **The 'Easy Way Out' Myth Busted:** A powerful new Rice University study confirms what many of you have likely felt: GLP-1 users face more judgment, even compared to those who don't lose weight! This isn't just about external perceptions; it's a call for us to proudly own the real, hard work *you're* putting into your health, despite the unfair narrative.
Read more →
Article
Gila·5/25/2026
FDA 503B Comment Deadline Is June 29 — What Compounded GLP-1 Users Should Do Now
The FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period closes June 29, 2026. If finalized, most $200-400/month telehealth compounded GLP-1 paths close. Here's what changes, what doesn't, and what to do this month.
Read more →
Article
Gila·5/25/2026
Medicare GLP-1 Bridge — What the $50 Copay Pilot Actually Covers (2026)
Medicare will pay $50/month for Wegovy, Zepbound KwikPen, and Foundayo from July 1, 2026 through December 31, 2027. Eligibility is BMI-anchored at therapy initiation, not today. The $50 doesn't count toward Part D deductible or the $2,100 out-of-pocket cap. Here's exactly who qualifies and what the fine print costs.
Read more →
Article
Gila·5/20/2026
Is Ozempic the 'Easy Way Out'? The Truth About GLP-1 Stigma
A 2026 Rice University study found people judge GLP-1 users more harshly than those who lost no weight at all. Here is what the research shows about the 'easy way out' myth — and why a GLP-1 is a tool, not a shortcut you should hide.
Read more →
Original
Gila·5/13/2026
GLP-1 and Muscle Mass: What the 2025-2026 Research Actually Says
❤️ **Protect Your Power!** New research confirms that while GLP-1s are incredible for weight loss, we absolutely need to be proactive about muscle preservation. The science shows we can lose significant lean mass, especially with medications like tirzepatide, making it critical to prioritize high protein intake (think 1.4-1.6g/kg daily!) and consistent resistance training to build a strong, resilient foundation for your new body!
Read more →
Original
Gila·5/13/2026
The Best Free GLP-1 Tracker Apps for Android in 2026
Seven free-or-freemium GLP-1 tracker apps on Google Play, ranked honestly. Shotsy is the strongest truly-free option (4.5 stars, 7K reviews). MyFitnessPal added free GLP-1 Support in April 2026. Plus: the Android-only Health Connect advantage iPhone users don't get.
Read more →
Original
Gila·5/13/2026
CagriSema vs Tirzepatide: The 22.7% Headline (and the Asterisk Nobody Mentions)
Novo Nordisk's CagriSema produced 22.7% weight loss in REDEFINE 1 — but lost head-to-head to tirzepatide (23.0% vs 25.5%) in REDEFINE 4, February 2026. FDA decision late 2026. Here's why patients on Mounjaro shouldn't wait.
Read more →
Original
Gila·5/9/2026
Retatrutide vs Tirzepatide: The Reta Hype, Tested (2026)
🚀 **Next-Gen GLP-1 Alert!** Lilly's investigational triple-agonist, Retatrutide, is showing jaw-dropping ~24% weight loss in trials, potentially outpacing Tirzepatide! While the numbers are exciting and hint at the future, remember this crucial truth: the real, lasting success on *any* medication comes from building those rock-solid habits that support you long-term, because sustained results are about more than just the scale.
Read more →
Original
Gila·5/9/2026
Foundayo vs Wegovy vs Zepbound: The 2026 Oral GLP-1 Decision Guide
💊 **Oral GLP-1 Game Changer!** Get ready for an exciting new landscape in oral GLP-1s! Our latest update reveals Foundayo (orforglipron) as the ultimate winner for convenience, offering the first daily pill with absolutely no food or water restrictions, making adherence a breeze. While injectable Zepbound still leads for maximum weight loss, we now have amazing new options to consider based on your lifestyle, desired weight loss, and budget, proving your journey is more personalized than ever.
Read more →
Article
Gila·4/30/2026
Compounded GLP-1s in 2026: What FDA's April 30 Proposal Means for 503B and 503A Patients
🚨 **Heads Up, Team!** The FDA just proposed changes that could impact compounded GLP-1 access from 503B facilities by 2026. This isn't immediate, but it's a call to action: connect with your prescriber now to proactively plan your transition to approved medications, ensuring your incredible progress continues seamlessly. Remember, your habits are your superpower, and we'll navigate any shifts together!
Read more →
Article
Gila·4/27/2026
GLP-1 Adherence Statistics 2026: Why Persistence Nearly Doubled
12-month persistence on weight-loss GLP-1s climbed from 33% in 2021 to 63% in 2024. Inside the latest Prime Therapeutics, KFF, and NEJM data — what the new numbers actually say about who stays on therapy, who stops, and why.
Read more →
Original
Gila·4/24/2026
The Best Free GLP-1 Tracker Apps for iPhone in 2026
Most free GLP-1 apps are freemium — the essentials are free but the useful stuff hides behind a paywall. A few are genuinely free. Here are the best free and meaningfully free GLP-1 tracker apps for iPhone in 2026, plus what still is not worth paying for.
Read more →
Article
Gila·4/24/2026
The Hidden GLP-1 Side Effects Clinical Trials Missed (Penn Study)
🩺 **Your Symptoms ARE Validated!** A groundbreaking Penn study used AI to analyze over 400,000 Reddit posts, uncovering GLP-1 side effects like irregular cycles and temperature changes that clinical trials often miss. This incredible research validates that if you're experiencing something "different," you're not alone, and your unique journey is helping us understand these medications even better!
Read more →
Article
Gila·4/18/2026
Mounjaro vs Ozempic vs Zepbound vs Wegovy (2026): The Honest Comparison
Four drugs, two active ingredients. Tirzepatide (Mounjaro/Zepbound) produces ~21% weight loss; semaglutide (Ozempic/Wegovy) ~15%. A clinically-honest breakdown across efficacy, side effects, cost, insurance, availability, and the lived experience — plus which one is probably right for you.
Read more →
Article
Gila·4/18/2026
Zepbound Side Effects Month-by-Month: The Real Timeline From Clinical Data
Most Zepbound side effects peak during dose escalation and fade within 2-4 weeks at each stable dose. Here is the month-by-month timeline from SURMOUNT clinical data — what to expect at 2.5mg, 5mg, 7.5mg, and higher doses, plus when to call your prescriber.
Read more →
Article
Gila·4/18/2026
Restarting Your GLP-1 After Quitting: What the 2026 Research Actually Says
🔄 **Restarting Your GLP-1? It's a Smart Reset!** New research reveals many people pause their GLP-1 journey, making restarting a common and powerful decision. This isn't a setback; it's an opportunity to learn from your initial experience and strategically recalibrate with your prescriber for durable, long-term success. Think of it as a new, informed chapter in your health journey!
Read more →
Article
Gila·4/18/2026
You're Not Broken: Why GLP-1s Don't Work for 1 in 10 People (2026 Research)
✨ **Your Body's Unique!** Game-changing research just dropped, showing that about 1 in 10 people carry genetic variants making GLP-1s less effective for them. This means if your medication isn't hitting as hard as expected, it's not your fault – it's fascinating biology, and precision medicine is on the horizon!
Read more →
Article
Gila·4/13/2026
GLP-1 vs Intermittent Fasting: Why Stacking Them Backfires (2026 Research)
Intermittent fasting alone produces 1-3% weight loss in trials. GLP-1 medications produce 15-22%. Stacking them rarely accelerates results and often increases muscle-loss risk. Here is what the 2026 research actually shows, why the food-noise paradox matters, and what to focus on instead.
Read more →
Article
Gila·4/13/2026
Ozempic Not Working Anymore? Why Your Medication Feels Different After Months
If you are 6 to 9 months into Ozempic and the medication has started feeling less effective, you are not imagining it and you are not broken. Three causes account for most of these reports: metabolic recalibration as your body adjusts to a smaller mass, behavioral drift as appetite habits quietly rebuild around the medication, and dropping cumulative serum exposure from missed or late doses. Here is what to actually check before escalating dose or switching to Mounjaro or Zepbound.
Read more →
Article
Gila·4/8/2026
I Tested 8 GLP-1 Tracker Apps. Only Two Actually Build Habits.
Shotsy vs GlucoPal vs 6 more: I tested 8 GLP-1 tracker apps for 2026 — the best free options for iPhone, which are just logs, and the two that actually help you build habits. Free vs paid picks and a real-search FAQ.
Read more →
Original
Gila·4/6/2026
Wegovy HD Approved: What the Higher 7.2mg Dose Means for Your Journey
The FDA approved Wegovy HD (semaglutide 7.2mg) on March 19, 2026. The STEP UP trial showed 20.7% mean weight loss vs 17.5% with standard 2.4mg. Designed for adults already tolerating the standard dose who need additional weight reduction. Available April 2026 as a single-dose pen.
Read more →
Original
Gila·4/6/2026
GLP-1 Medications May Reduce Depression and Anxiety: What the New Research Shows
A major 2026 Lancet Psychiatry study of 100,000 people found GLP-1 medications reduced depression risk by 44% and anxiety by 38%. The within-individual study design compared the same patients on and off treatment, revealing significant mental health benefits including 42% fewer psychiatric hospitalizations and 47% lower substance use disorders.
Read more →
Original
Gila·4/6/2026
$14 a Month Semaglutide Is Real. Why You Probably Still Cannot Get It.
Generic semaglutide launched in India at $14/month on March 20, 2026. Foundayo entered the US at $149/month. Medicare added obesity coverage via the BALANCE Model. Here is what generic GLP-1 access actually means in 2026 — and why US generic Ozempic is still 5+ years away.
Read more →
Original
Gila·4/6/2026
Are Your GLP-1 Habits Strong Enough? Take This Free Self-Assessment
A free 10-question self-reflection quiz to explore how strong your daily habits are on your GLP-1 journey. Not a clinical test — a gentle mirror for where you are and where to focus next.
Read more →
Original
Gila·4/6/2026
Stopping Ozempic Cold Turkey: What the Research Actually Says (2026)
Thinking about stopping your GLP-1 medication abruptly? Research shows 67% of weight is regained within 12 months. Here is what happens to your body and how to taper safely.
Read more →
Original
Gila·4/6/2026
Orforglipron Approved: Lilly's GLP-1 Pill Is Here — What It Means for Your Journey
The FDA approved orforglipron — Eli Lilly's once-daily GLP-1 pill — on April 1, 2026. No injections needed. Here's what it means for people on or considering GLP-1 medications.
Read more →
Original
Gila·4/6/2026
Zepbound Savings Card: Complete Guide to Eligibility, Discounts, and How to Save in 2026
Everything you need to know about the Zepbound savings card in 2026 — eligibility requirements, how much you can save, how to apply, and what to do if you don't qualify.
Read more →
Original
Gila·3/30/2026
GLP-1 Prices Just Collapsed. Here is What You Will Actually Pay in 2026.
GLP-1 list prices fell 50% in 12 months. Oral Wegovy launched at $675/month vs $1,349 injection. Foundayo entered at $149/month. Indian generics hit $14/month. Here is the full 2026 cost landscape and what each path actually costs you.
Read more →
Original
Gila·3/30/2026
400,000 People Took the Wegovy Pill in 10 Weeks. Here Is What That Means for You.
Novo Nordisk reports 400,000 Americans started oral Wegovy in 10 weeks — the fastest US drug launch in history. At $675/month list price (50% below the injection) and $499 with the savings card, the pill broke the cost barrier for first-time patients. Here is what the launch reveals and what it means for your access.
Read more →
Original
Gila·3/30/2026
GLP-1 Gastroparesis: What the Research Actually Says About Stomach Paralysis Risk
GLP-1 gastroparesis risk explained with real data. The JAMA study found a 3.67x increased risk — here's what that actually means for you, who's most at risk, and what to watch for.
Read more →
Article
Gila·3/22/2026
The FDA Warned 30 GLP-1 Telehealth Companies. Is Yours on the List?
The FDA warned 30 telehealth companies selling unapproved GLP-1 medications. If you order Ozempic, Wegovy, or compounded semaglutide online, here is how to verify your source is safe — and the red flags that mean you should stop ordering immediately.
Read more →
Article
Gila·3/22/2026
GLP-1s Are Tools, Not Solutions: Building What Lasts
❤️ **Build to Last:** This Gila article powerfully reminds us that GLP-1s are an incredible window of opportunity, not a permanent solution. Let's use this precious time to intentionally build lasting habits and a strong identity as someone who prioritizes their health, because *what* you build now is what truly persists beyond the medication.
Read more →
Article
Gila·3/22/2026
Oral GLP-1 Pills Are Here: What You Need to Know
FDA approved the first oral GLP-1 pill for weight loss. Compare pills vs injections — efficacy, convenience, cost, and who they work best for.
Read more →
Article
Gila·3/22/2026
Hair Loss on GLP-1 Medications: Causes and Prevention
Experiencing hair loss on Ozempic or semaglutide? Learn why rapid weight loss causes telogen effluvium, how to prevent it, and when hair regrows.
Read more →
Article
Gila·3/22/2026
GLP-1 Dosage Guide: Titration Schedules Explained
GLP-1 dosage guide: titration schedules for Ozempic, Wegovy, Mounjaro, and Zepbound. Why slow titration matters and what to expect at each dose level.
Read more →
Article
Gila·3/22/2026
Exercise on GLP-1 Medications: A Complete Guide
Working out on Ozempic or GLP-1 medication? A complete exercise guide covering resistance training, cardio, energy management, and realistic starting points.
Read more →
Article
Gila·3/22/2026
Managing Constipation on GLP-1 Medications
Constipation on Ozempic or Mounjaro? Learn why GLP-1 medications cause constipation, proven remedies that work, and when to talk to your doctor.
Read more →
Article
Gila·3/22/2026
Ozempic Face: What It Is and What You Can Do
Ozempic face explained: what causes facial volume loss on GLP-1 medications, why rate of weight loss matters, and practical steps to protect your appearance.
Read more →
Article
Gila·3/22/2026
Ozempic vs Mounjaro: Which GLP-1 Is Right for You?
Ozempic vs Mounjaro: compare semaglutide and tirzepatide side by side. Weight loss data, side effects, dosing, cost, and which GLP-1 may suit your needs.
Read more →
Article
Gila·3/22/2026
How Much Do GLP-1 Medications Cost Without Insurance?
GLP-1 medication cost without insurance: Ozempic, Wegovy, Mounjaro, and Zepbound prices, savings programs, and ways to reduce your monthly cost.
Read more →
Article
Gila·3/22/2026
Alcohol and GLP-1 Medications: What to Know
Drinking on Ozempic or Mounjaro? Learn how GLP-1 medications change alcohol tolerance, why many people drink less, and practical guidelines for your safety.
Read more →
Article
Gila·3/22/2026
Prevent Muscle Loss on GLP-1s: Protein and Exercise Guide
Up to 40% of GLP-1 weight loss can be muscle. Learn protein targets, resistance training basics, and body composition strategies to preserve lean mass.
Read more →
Article
Gila·3/22/2026
Weight Regain After Stopping GLP-1s: What Research Shows
Research shows two-thirds of weight is regained after stopping GLP-1 medication. Learn what protects against regain and how to keep your progress.
Read more →
Article
Gila·3/22/2026
First Month on GLP-1s: Side Effects and What to Expect
Week-by-week guide to your first month on Ozempic, Wegovy, or Mounjaro. Common side effects, timelines, coping strategies, and when to call your doctor.
Read more →
Article
Gila·3/22/2026
What to Eat on Ozempic and Wegovy: Nutrition Guide
Practical nutrition guide for Ozempic and Wegovy users. Learn protein targets, hydration needs, and how to nourish your body when appetite is suppressed.
Read more →
Article
Gila·3/22/2026
GLP-1 Mental Health Effects: Mood Changes and Anxiety
GLP-1 medications can affect mood, cause anxiety, or unmask emotions food was covering. Understand why it happens and practical coping strategies.
Read more →
Article
Gila·3/22/2026
GLP-1 Nausea Relief: 8 Remedies That Actually Work (2026 Guide)
Nausea is the most common GLP-1 side effect, affecting up to 44% of users. These 8 evidence-based remedies — from meal timing to ginger to dose adjustment — can help you manage it without quitting.
Read more →
Article
Gila·3/22/2026
GLP-1 Weight Loss Plateau: Why It Happens and How to Break Through
Hit a weight loss plateau on Ozempic, Wegovy, or Mounjaro? Metabolic adaptation is the most common cause. Here are 6 evidence-based strategies to restart your progress.
Read more →
Article
Gila·3/22/2026
Ozempic Stopped Working? 5 Real Reasons and What to Do Next (2026)
Ozempic plateau? Here are the 5 evidence-based reasons your GLP-1 medication stalled — metabolic adaptation, receptor desensitization, behavioral drift, injection site issues, and stress — plus exactly what to do about each one.
Read more →
Original
Gila·3/12/2026
GLP-1 Community Stories: You Are Not Alone
Real stories from people on Ozempic, Wegovy, and Mounjaro. Side effects, identity shifts, food grief, and the power of community support.
Read more →
Original
Gila·3/12/2026
GLP-1 Habits That Last After You Stop Medication
Build lasting habits while on GLP-1 medication. Five evidence-based strategies for anchor meals, movement, and identity work that outlast your prescription.
Read more →
Original
Gila·3/12/2026
Food Noise on GLP-1s: What It Is and How to Navigate It
Food noise is the constant mental chatter about eating. Learn why GLP-1 medications quiet it, what happens when it returns, and how to build lasting change.
Read more →
Original
Gila·3/12/2026
Why 53% of GLP-1 Users Quit: Causes and Solutions
A JAMA study found 53.6% of GLP-1 users stop within 12 months. Discover why people quit Ozempic and three actionable steps to stay on track.
Read more →
Article
Ada — Gila·3/9/2026
What Is Food Noise? The Science Behind GLP-1s and Quiet Minds
Food noise is the constant, intrusive mental chatter about food that millions experience daily. This deep dive explains the neuroscience of how GLP-1 medications like semaglutide and tirzepatide quiet food noise by modulating the hypothalamus and reward pathways, distinguishes food noise from physiological hunger, and provides three evidence-based strategies — trigger-food visibility friction, small-plate pacing, and anchor meal templates — for managing it. Backed by research from JAMA, Cleveland Clinic, and NHS guidance.
Read more →
Article
Matt — Gila·3/9/2026
Oral GLP-1 Pills 2026: Wegovy, Foundayo, and Orforglipron Compared
Three oral GLP-1s now have FDA approval: Wegovy pill ($675/mo, Dec 2025), Foundayo orforglipron ($149/mo, April 2026), and Rybelsus (off-label). Trial data shows oral matches injection efficacy within 1-3pp. Here is the full comparison: efficacy, dose timing, side effects, cost.
Read more →Article
Matt — Gila·3/9/2026
Building Habits That Outlast Your Prescription
Your GLP-1 medication opens a window for behavior change — this guide shows you what to build inside it. Covers 16 clinically-corroborated practices organized into actionable categories: morning hydration anchors, post-meal walks, protein-first eating, strength training for lean mass preservation, food noise defense through environmental design, sleep consistency, weekly self-assessment, side effect management protocols, and structured clinician communication. Every practice backed by PubMed research, NICE guidelines, and NHS guidance.
Read more →Article
Ada — Gila·3/9/2026
The Ozempic Personality: Why GLP-1s Change More Than Your Weight
Beyond appetite suppression, GLP-1 medications modulate reward circuits across the brain — reducing food cravings, alcohol consumption, and even compulsive behaviors. This article explores the identity transformation that follows: food grief, phantom fat, social identity shifts, and the impostor syndrome of a changed body. Backed by research from JAMA Psychiatry (107,000+ participants), The Lancet, Psychology Today, and the Endocrine Society. Includes guidance on when to seek professional support.
Read more →Article
Matt — Gila·3/9/2026
Why 53.6% of GLP-1 Users Quit Within a Year (And How to Be in the Other Half)
A JAMA Network Open study of 125,474 adults found that 53.6% discontinue GLP-1 medications within one year. This evidence-based analysis examines the six key reasons — side effects, cost, supply shortages, unrealistic expectations, premature cessation, and lack of support structure — and provides clinically-grounded strategies for staying on track, including the Weekly Plateau Scoreboard, Rebound Early-Warning Threshold, and structured side effect management. Anchored by STEP 4 trial data showing 14.8 percentage points difference between continuing and stopping.
Read more →
Article
The Guardian Health·3/6/2026
Weight-loss drugs alone will not solve UK’s obesity crisis, says Chris Whitty
❤️ **Beyond the Rx:** The UK's Chief Medical Adviser, Chris Whitty, offers a critical perspective, reminding us that while GLP-1 medications are powerful tools, they're not a standalone solution for the obesity crisis. This emphasizes that lasting success on our journey integrates these incredible tools with essential lifestyle changes and a commitment to creating healthier food environments for long-term well-being!
Read more →
Article
The Guardian Health·3/6/2026
Weight-loss jab could be made for $3 a month, study finds
🌍 **Cost Revolution Ahead!** A groundbreaking study reveals that semaglutide, the powerful ingredient in Ozempic and Wegovy, could potentially be manufactured for just $3 a month as global patents expire! This fantastic news means these life-changing medications could soon become vastly more affordable and accessible to millions around the world, opening doors to better health and supporting our global community in the fight against obesity and diabetes.
Read more →
Article
Central Oregon Daily·3/6/2026
GLP-1 price cuts announced for Wegovy, Ozempic
💰 **Prices Coming Down!** Here's some really encouraging news: Novo Nordisk just announced they're cutting the list prices for Wegovy and Ozompic to $675 per month starting in 2027. While insurance coverage still matters, this is a meaningful step toward making your GLP-1 journey more affordable and accessible. We've been cheering for solutions that help more of our community members access these life-changing medications, and price reductions are a big part of that picture!
Read more →
Article
STAT News·3/6/2026
Novo Nordisk's Wegovy and Ozempic shots could be made for as little as $3 a month, analysis finds
🌍 **Global Health Wins!** New research shows that generic versions of semaglutide could be produced for just $3 a month, potentially transforming access in low- and middle-income countries. Patents are set to expire in India, China, Canada, Brazil, and Turkey this year. This isn't just about affordability — it's about ensuring that more of our global community gets the chance to experience the freedom and health improvements that GLP-1s can bring, regardless of where they live!
Read more →
Article
X/Twitter·3/5/2026
Ozempic may reduce the mortality risk from colon cancer — GLP-1 users were less than half as likely to die within 5 years
🐦 **Trending on X: More Than Just Weight Loss!** Dr. Rhonda Patrick dropped some groundbreaking news, showing GLP-1s like Ozempic might slash colon cancer mortality risk by over 50%! This isn't just about the scale, folks; it's a powerful reminder of the deep, systemic health benefits these medications can offer for our long-term well-being.
Read more →
Article
Drugs.com·3/5/2026
Zepbound vs Mounjaro: Comparison Guide for Weight Loss and Diabetes Treatment
💡 **Know Your Meds:** Drugs.com published a fantastic comparison of Zepbound and Mounjaro! This deep dive is crucial for understanding the nuances of these powerful tools, whether you're already on one or exploring which might be the best fit for your unique journey. Knowledge is power, team!
Read more →
Article
The Guardian Health·3/4/2026
Weight loss drugs may stop people getting addicted to drugs and alcohol, study finds
✨ **Beyond Weight Loss:** Incredible new research suggests GLP-1 medications could offer an exciting additional benefit: potentially reducing the risk of addiction to alcohol and drugs! This glimpse into how these medicines influence our brain's reward pathways is truly groundbreaking. It highlights the expanding positive impact these tools might have on our overall wellness journey as more is understood.
Read more →
Article
ScienceDaily·3/4/2026
Ozempic-like weight loss drugs may help the heart recover after a heart attack
❤️ **Heart-Smart News!** Get this – new research shows GLP-1 medications might actually help your heart recover after a heart attack by boosting blood flow in those tiny vessels! This isn't just about the scale; it's exciting news for your overall cardiovascular health and highlights another incredible benefit of these medications for us.
Read more →
Article
MedPage Today·3/2/2026
GLP-1 Drugs May Work Differently in Women
💖 **Unique Responses:** A new meta-analysis highlights that women on GLP-1 medications tend to experience greater average weight loss than men, likely due to biological differences like hormones. This insight reminds us that our bodies respond uniquely, but the powerful benefits of GLP-1s, combined with consistent effort, are making incredible strides for everyone on this journey!
Read more →
Article
Noom·3/1/2026
GLP-1 Side Effects: What to Expect & How to Manage Them
💡 **Side Effect Savvy:** Understanding potential GLP-1 side effects is key to a smooth journey! This Noom guide gives us excellent, practical tips on what to expect and, more importantly, how to proactively manage them. Let's empower ourselves with this knowledge to stay on track!
Read more →
Article
UVA Health·3/1/2026
How to Tame GLP-1 Side Effects: 6 Tips
💚 **Navigate Side Effects With Ease!** Nausea, constipation, and GI changes are real — and you're not alone if you've experienced them. UVA Health just shared six powerful tips for managing these side effects: eat slowly, stay hydrated, avoid strong smells, rotate injection sites, and give your body time to adjust. Most people find that side effects improve with these strategies and proper support. Your comfort matters, and you deserve to feel your best on this journey!
Read more →
Article
Psychology Today·2/28/2026
GLP-1s and the Thin Ideal
🤔 **Beyond the Scale: GLP-1s and Mental Well-being** Psychology Today highlights a crucial point: while GLP-1s are powerful tools, we must actively guard against the cultural pressure of the "thin ideal" and prioritize our mental health. It's so important to focus on a healthy relationship with our bodies and self-worth, rather than just chasing a number, to ensure a truly sustainable and joyful journey!
Read more →
Video
Strong and Steady with Betty·2/28/2026
Week 57: I Was Afraid to Share This | GLP-1 Update (95 lbs down)
🍿 **Approaching Maintenance: What's Next?** You HAVE to watch Strong and Steady with Betty this week! She's down an incredible 95 lbs and shares the raw, honest truth about the mental and physical uncertainty of entering the maintenance phase. This video is a must-watch to feel less alone as we navigate this powerful journey together!
Read more →
Video
Bazgha Khalid, MD·2/27/2026
Weight loss stall on GLP-1? Weight Loss Doctor Explains Hidden Insulin Resistance
🍿 **Stall Breaker Alert!** If your GLP-1 journey has hit a frustrating plateau, you *have* to watch this video. Dr. Bazgha Khalid, an obesity medicine expert, dives deep into the often-missed link between weight loss stalls and hidden insulin resistance, explaining how to test for it and what strategies can finally get the scale moving again for us!
Read more →
Video
Jack Cooper·2/27/2026
Retatrutide Explained: Benefits, Risks & New Data
🍿 **Your Retatrutide Blueprint!** If you're hearing the buzz about Retatrutide, Jack Cooper's video is an absolute must-watch! He breaks down the science, clinical data, benefits, and potential side effects so we can all get the full, evidence-based picture. Don't form an opinion until you've seen this – it's crucial for staying informed on your journey!
Read more →
Article
Nature International Journal of Obesity·2/27/2026
Long-term outcomes of metabolic and bariatric surgery: a 10-year study of effectiveness and predictors
❤️ **Long-Term Success with MBS!** A fantastic new 10-year study in *Nature* confirms metabolic and bariatric surgery (MBS) as a seriously effective long-term solution for obesity, with RYGB showing superior outcomes. This is incredible news for those considering or on this journey, showing us that sustained success is absolutely achievable! It also spotlights how crucial early weight loss and your baseline BMI can be for predicting your long-term wins – keep that momentum going!
Read more →
Article
Scientific American·2/26/2026
Head-to-head trial shows Eli Lilly’s oral GLP-1 orforglipron outperforms oral semaglutide
❤️ **Oral GLP-1 Power-Up on the Horizon!** Get ready, because a new head-to-head trial shows Eli Lilly's oral GLP-1, orforglipron, could offer even greater weight loss and blood sugar reduction than current oral semaglutide options. This is fantastic news, hinting at more powerful, potentially accessible oral choices to empower your journey, while reminding us to always discuss side effects with our docs!
Read more →
Video
Brittany Rose GLP1·2/26/2026
GLP1 Weight loss Stalls: WHY they happen and HOW to conquer them
🎥 **Stall Buster Alert!** Hitting a weight loss plateau on GLP-1s can feel incredibly frustrating, but guess what? It's a super common part of the journey! Brittany Rose delivers an amazing video breaking down *why* these stalls happen and, more importantly, *how* to conquer them. You absolutely need to watch this for actionable strategies to reignite your progress and keep that momentum high!
Read more →
Article
Scientific American·2/26/2026
Cells in the body remember obesity. Here’s what that means for weight loss
❤️ **Your Cells Have a Memory!** Fascinating research from Scientific American reveals that our fat and immune cells can actually "remember" obesity, leaving epigenetic imprints that make weight regain super challenging. This helps us understand why weight loss maintenance is a battle, but also lights the way for new strategies and ongoing research to make *your* lasting success a reality!
Read more →
Video
Faye In The City·2/26/2026
Chile, I Tried Weight Loss Injections For Three Months! | My SUPER Honest FINAL Update
🍿 **Faye's 3-Month GLP-1 Journey!** You absolutely have to watch Faye's super honest final update after three months on a Tirzepatide compound. She dives deep into her personal experience, giving us all invaluable insights into what the initial months on medication can really look like!
Read more →
Article
Hopkins MD·2/25/2026
Managing GLP-1 Side Effects: Our Top Tips for Success
👩⚕️ **Expert Tips for Success!** Hopkins MD just shared their top strategies for managing GLP-1 side effects and making your journey smoother. From timing meals to staying hydrated, from injection site rotation to patience during adjustment periods — these expert tips are gold. Medical professionals understand that your comfort and success matter, and they're committed to helping you navigate every step. You're not alone in this, and there are real solutions!
Read more →
Article
Greatist·2/24/2026
New Study Says Limiting Bedtime Eating Boosts Overall Health
❤️ **Nighttime Nudge!** A new study spotlighted by Greatist shows that finishing your last meal three hours before bed is a game-changer for our health, improving blood pressure, heart rate, and glucose levels! This simple habit can seriously boost your metabolic health and support your weight loss journey, proving that *when* you eat can be as important as *what* you eat. Let's make this small shift tonight for big health wins!
Read more →
Article
taaft·2/24/2026
Preventing obesity-related cancer with the revolution in obesity management: the challenges of undertaking a clinical trial and potential solutions
❤️ **Beyond Weight Loss: A Potential Shield Against Cancer!** This compelling article dives into the incredible potential of GLP-1 medications to do more than just help us lose weight; they might also play a crucial role in preventing obesity-related cancers. While clinical trials are underway to confirm this, it's thrilling to imagine our weight loss journey also becoming a powerful strategy for long-term health and disease prevention!
Read more →
Article
Psychology Today·2/23/2026
Hunger Games: Why Diets Fail and Weight Loss Medicines Succeed
🤯 **The Real Enemy: Hunger!** This brilliant Psychology Today article confirms what we've often felt – our bodies' intricate hunger signals, not a lack of willpower, are why traditional diets falter. It beautifully explains how GLP-1s help us win the 'Hunger Games' by finally addressing those biological mechanisms. This empowers us to focus on truly managing hunger for sustainable, joyful weight loss!
Read more →
Video
Adem - Run For Your Life·2/23/2026
What “Food Noise” Really Feels Like (And How Mounjaro Changed It)
🍿 **Must-Watch: What's "Food Noise"?** Adem's video is a game-changer for understanding that relentless mental chatter about food – he only realized what "food noise" was once Mounjaro silenced it! If you've ever felt that constant pull towards snacks or wondered if your relationship with food is "normal," his incredibly honest account, including taking a break and returning to medication, offers powerful insights you absolutely need to see.
Read more →
Video
Regenics Women's Health·2/21/2026
Why Ozempic “Stops Working” (It’s Not What You Think)
🍿 **Ozempic Stall? Debunk the Myth!** If you're feeling like your GLP-1 medication has stopped working, this video is a game-changer you *have* to see! It brilliantly breaks down the top 10 subtle, fixable habits that unknowingly sabotage your progress, reminding us all that often, it's not the medication, but our approach, that needs a high-five and a tweak!
Read more →
Article
@FitnessTransformation·2/21/2026
Before & After: 6 months on Mounjaro
Viral Instagram content with 1,250,000 likes
Read more →Article
@HealthJourney·2/20/2026
POV: You lost 50lbs on GLP-1 and your family doesn't recognize you
Viral TikTok content with 8,500,000 views
Read more →Article
@HealthyEatingWithMe·2/20/2026
What I eat on Ozempic for maximum results
Viral Instagram content with 890,000 likes
Read more →Article
X/Twitter·2/20/2026
This GLP-1 transformation has the internet SHOOK 😳
Viral X/Twitter content with 2,500,000 views
Read more →
Video
Bazgha Khalid, MD·2/20/2026
Ozempic & Mounjaro Side Effects: How to Fix Nausea, Burps, and Fatigue
🍿 **Side Effect Survival!** Are those GLP-1 side effects like nausea and "sulfur burps" dimming your shine? Dr. Bazgha Khalid, a board-certified Internal Medicine & Obesity Medicine expert, delivers the ultimate survival guide in this must-watch video! She shares doctor-approved hacks, clinical data, and even the exact questions you need to ask your doctor to feel amazing and stay on track with your journey!
Read more →
Article
Harvard Health·2/20/2026
GLP-1 diabetes and weight-loss drug side effects: Ozempic face and more
🌟 **Beyond the Scale!** Harvard Health explores what people are actually experiencing on GLP-1s — from the expected nausea to the less-talked-about changes like facial changes (sometimes called 'Ozempic face'). Understanding the full picture helps you feel prepared and less surprised by what your body might experience. Knowledge is power, and knowing what to expect means you can navigate your journey with confidence and support!
Read more →